Oh hey there…another Top 5 topics you need to know from outside Europe this week.
Enjoy and if you have time, give us some feedback!
BREAKTHROUGH TABLET PREVENTS HIV INFECTION IN UP TO 92% OF HIGH RISK CASES
HIV Tablet ‘Truvada‘: San Francisco health Insurance firm Kaiser Permanente published a study on Tuesday showed out of the 657 ‘high risk of HIV’ patients taking Truvada, none contracted HIV over a 3-year period marking a massive milestone in the battle against AIDS.
READ MORE ON BUSINESS INSIDER UK…
CRISPR CAS-9 GENOME EDITING COMPLEX DELIVERED TO NUCLEUS BY DNA VEHICLE
CRISPR-Cas9 genome editing complex delivered to cell nucleus by engineered extracellular DNA-based transport package dubbed ‘Nanoclews’. Shown to be an efficient delivery method of Cas9, it has been demonstrated both in vivo and in vitro.
WATCH ACTIN-MYOSIN INTERACT IN VIVO IN SUPER-HIGH RESOLUTION
S: Betzig Lab, HHMI/Janelia Research Campus
“Scientists can now watch dynamic biological processes with unprecedented clarity in living cells using new imaging techniques. The new methods dramatically improve on the spatial resolution provided by structured illumination microscopy, one of the best imaging methods for seeing inside living cells.”
Cholesterol Drug Competition: Alnylam’s candidate better than Amgen’s?
A early-stage drug trial by Alnylam has shown promising results regarding removal of liver protein PCSK9, responsible for serum cholesterol regulation. PCSK9 is a hot topic for big pharma piplines, including Sanofi, Regeneron and Amgen in the race to fix high-cholesterol.
READ MORE ON BOSTON BUSINESS JOURNAL…
The CRISPR-Cas9 has even more millions in funding thrown at it
“Cambridge-based Intellia Therapeutics has secured $70 million to progress medicines that cure diseases by cutting or repairing mutated genes. The funding comes less than a month after gene-editing company Editas Medicines secured $120 million for its gene-editing therapies, and is only the latest example of companies that are taking advantage of the promising new area of medicine using a process known as CRISPR/Cas9.”
READ MORE ON BOSTON BUSINESS JOURNAL…